1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ceptaris Therapeutics Inc. - Product Pipeline Review - 2013

Ceptaris Therapeutics Inc. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 22 pages

Ceptaris Therapeutics Inc. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Ceptaris Therapeutics Inc. - Product Pipeline Review - 2013” provides data on the Ceptaris Therapeutics Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ceptaris Therapeutics Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ceptaris Therapeutics Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ceptaris Therapeutics Inc. - Brief Ceptaris Therapeutics Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ceptaris Therapeutics Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ceptaris Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ceptaris Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ceptaris Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ceptaris Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ceptaris Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ceptaris Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ceptaris Therapeutics Inc. and identify potential opportunities in those areas.

Table Of Contents

Ceptaris Therapeutics Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Ceptaris Therapeutics Inc. Snapshot 4
Ceptaris Therapeutics Inc. Overview 4
Key Information 4
Key Facts 4
Ceptaris Therapeutics Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Ceptaris Therapeutics Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Ceptaris Therapeutics Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Ceptaris Therapeutics Inc. - Drug Profiles 10
Dermatology Program 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
mechlorethamine hydrochloride 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
YT-1006 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Ceptaris Therapeutics Inc. - Pipeline Analysis 13
Ceptaris Therapeutics Inc. - Pipeline Products by Therapeutic Class 13
Ceptaris Therapeutics Inc. - Pipeline Products By Target 14
Ceptaris Therapeutics Inc. - Pipeline Products by Route of Administration 15
Ceptaris Therapeutics Inc. - Pipeline Products By Mechanism of Action 16
Ceptaris Therapeutics Inc. - Recent Pipeline Updates 17
Ceptaris Therapeutics Inc. - Dormant Projects 19
Ceptaris Therapeutics Inc. - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables

Ceptaris Therapeutics Inc., Key Information 4
Ceptaris Therapeutics Inc., Key Facts 4
Ceptaris Therapeutics Inc. - Pipeline by Indication, 2013 6
Ceptaris Therapeutics Inc. - Pipeline by Stage of Development, 2013 7
Ceptaris Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 8
Ceptaris Therapeutics Inc. - Preclinical, 2013 9
Ceptaris Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 13
Ceptaris Therapeutics Inc. - Pipeline By Target, 2013 14
Ceptaris Therapeutics Inc. - Pipeline By Route of Administration, 2013 15
Ceptaris Therapeutics Inc. - Pipeline Products By Mechanism of Action, 2013 16
Ceptaris Therapeutics Inc. - Recent Pipeline Updates, 2013 17
Ceptaris Therapeutics Inc. - Dormant Developmental Projects,2013 19

List of Figures

Ceptaris Therapeutics Inc. - Pipeline by Indication, 2013 6
Ceptaris Therapeutics Inc. - Pipeline by Stage of Development, 2013 7
Ceptaris Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 8
Ceptaris Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 13
Ceptaris Therapeutics Inc. - Pipeline By Route of Administration, 2013 15
Ceptaris Therapeutics Inc. - Pipeline Products By Mechanism of Action, 2013 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016’, provides in depth analysis ...

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.